Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two injections per year to one against HIV. "It is a hopeful step and the study data are positive.

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a

A groundbreaking annual injection designed to protect against Human Immunodeficiency Virus (HIV) has successfully